Mylan chief executive gives inaccurate depiction of profits during congressional hearing — 6 things to know

In a congressional hearing last week, Mylan chief executive Heather Bresch did not give an accurate number concerning how much the company made from a two-pack of EpiPens, according to The Washington Post.

Here are six things to know:

1. Ms. Bresch told legislators Mylan made profits of $100 per two-pack of EpiPen, which is valued at $608.

2. However, The Washington Post notes the profits Ms. Bresch described were calculated after taking the 37.5 percent U.S. tax rate into account.

3. However, that rate is more than five times the overall tax rate that Mylan paid in 2015. Many tax specialists put Mylan's actual U.S. tax rate at zero.

4. Mylan lowered its effective tax rate below the U.S. tax rate by moving its headquarters to the Netherlands. Robert Willens, an independent tax expert, told The Washington Post, Mylan's U.S. tax rate "is close to zero, a very, very low rate."

5. In a statement, a Mylan spokesperson defended the company's profits, saying, "Tax is typically included in a standard profitability analysis, and the information provided to Congress has made clear that tax was part of the EpiPen Auto-Injector profitability analysis. It also is important to note that use of a statutory tax rate for the jurisdiction being analyzed (in this instance, the U.S.) is standard."

6. Rep. Elijah E. Cummings (D-Md.) told Mylan in a statement the company had until the end of this week to give legislators additional documentation.

More healthcare news:
NY-based Rochester Regional Health plans ambulatory care center: 3 thoughts
AmSurg receives 'buy' rating — 5 notes
Conifer Health to handle value-based care services for Canopy Health in CA: 3 things to know

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months